New Drugs Approved in 2022

Area of Science:

• Pharmaceuticals and Regulatory Science
• Drug Development and Approval
• Medical Therapeutics

Background:

• The US Food and Drug Administration (FDA) plays a critical role in evaluating and approving new medications.
• Understanding trends in novel drug approvals provides insight into therapeutic advancements and regulatory practices.
• Expedited review pathways aim to accelerate the availability of important new medicines.

Purpose of the Study:

• To summarize the novel drugs approved by the FDA in 2022.
• To analyze the utilization of expedited review pathways for these approvals.
• To identify the proportion of novel drugs approved for rare disease treatment.

Main Methods:

• Review of FDA novel drug approval data for the calendar year 2022.
• Categorization of approvals based on review pathway (standard vs. expedited).
• Analysis of drug indications to identify those for rare diseases.

Main Results:

• A total of 37 novel drugs were approved by the FDA in 2022.
• 65% (24 out of 37) of these novel drug approvals utilized an expedited review pathway.
• 54% (20 out of 37) of the approved novel drugs were indicated for the treatment of rare diseases.

Conclusions:

• Expedited review pathways were extensively used for novel drug approvals in 2022.
• A significant portion of novel drug approvals in 2022 focused on rare disease treatments.
• The data suggests a regulatory emphasis on accelerating access to innovative therapies, especially for rare conditions.